Table of Contents
Contracts & Grants
Information is courtesy of the Office of Sponsored Projects. Each listing includes the faculty member's name and school(s) appointments at The University of Texas Health Science Center at Houston, contracting or granting agency, funding amount and project title.
Catherine G. Ambrose, Medical School (MS), Zimmer, $80,947, Biomechanical Evaluation of Anatomic Contoured Locking Plates for Periarticular Fractures; Zimmer, $119,770, Evaluation of Trabecular Metal Implants and Antibiotic-Impregnated Microspheres in Osteomyelitis; Zimmer, $88,615, Effect of NSAIDs on Bony Integration; Zimmer, $214,633, Evaluation of Trabecular Metal Implants and Biodegradable Microspheres Impregnated with BMP2.
Jason L. Anthony, MS, Kellogg Foundation, $1,691,965, Promoting School Readiness through The Texas Early Education Model and Raising a Reader.
Frank C. Arnett Jr., MS, National Institutes of Health (NIH), $27,774,045, Center for Clinical and Translational Sciences (CCTS).
Ali Azizzadeh, MS, Cordis Corporation, $27,016, Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy.
Staley A. Brod, MS, Questcor Pharmaceutical, $101,614, Evaluation of Plasma Cortisol Concentrations after Subcutaneous and Intramuscular Administration of H.P. Acthar Gel in Healthy Volunteers; Abbott Laboratories, $432,515, A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Safety, Tolerability and Efficacy Study of the Human Anti-Il-12 Antibody ABT-874 in Subjects with Multiple Sclerosis with a 24-Week Double-Blind, Active Extension Phase.
Louvenia Carter-Dawson, MS, University of Houston, $59,217, Behavioral Measures of Vision.
George Delclos, School of Public Health (SPH), Baylor College of Medicine, $68,613, Innate Immunity in Allergic Airway Inflammation of Asthma.
Pamela M. Diamond, SPH, The University of Texas at San Antonio, $17,654, Interventions for Adherence to Oral Antipsychotic Medications in Schizophrenia.
Carlos A. Dumas, MS, Texas Academy of Family Physicians Foundation, $4,999, Pilot Project Determining Risk Factors for Coronary Artery Disease in Bangladeshi Immigrant Men 35 Years and Older Living in Houston, Texas.
Charles D. Ericsson, MS, Cubist Pharmaceuticals Inc., $3,640, Infectious Diseases Grand Rounds - Speaker Edward Septimus.
Linda Ewing-Cobbs, MS, University of Houston, $111,689, Cognitive, Instructional and Neuroimaging Factors in Math.
Craig A. Field, SPH, NIH, $2,441,564, Multidisciplinary Approach to Reduce Injuries and Alcohol Problems.
Lorraine Q. Frazier, School of Nursing (SON), Texas Medical Center Howell Fund, $15,000, Promoting the Cardiovascular and Mental Health of Economically Disadvantaged Women Hospitalized for Acute Respiratory.
Millicent E. Goldschmidt, MS and Graduate School of Biomedical Sciences (GSBS), Cooley & Cooley Ltd., $12,000, Antimicrobial Activity of Doc's Best Copper Cement.
Nicole R. Gonzales, MS, University of Medicine & Dentistry of New Jersey, $105,754, Carotid Revascularization Endarterectomy vs. Stent Trial.
Adelaide A. Hebert, MS, Biomedical Development Corporation, $21,482, Novel Topical Treatment of Eczema; Biomedical Development Corporation, $27,240, Novel Topical Treatment for Post-Herpetic Neuralgia; Allergan Inc., $159,256, A Multi-Center, Open-Label Study of the Safety and Efficacy of Repeated Treatments with Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex for Primary Axillary Hyperhidrosis in Adolescents.
Keith Hoots, MS and GSBS, Bayer Corporation, $29,300, A Prospective Controlled Study on the Effect on Bleeding Events and Joint Function in Young Adults with Severe Hemophilia A after Six Months Regular Treatment Schedule Compared to On-Demand Treatment.
Thomas L. Huff, Dental Branch (DB), Zimmer Dental Inc., $20,000, Duser Alliance Educational Grant.
Barry D. Kahan, MS and GSBS, Kyorin Pharmaceutical Co. Ltd., $281,192, Development of KRP 203; Novartis Pharmaceuticals Corp., $301,332, Conversion from Mycopenolate Mofetil to Sodium Mycophenolic Acid.
Susan C. King, MS, Houston Endowment Inc., $450,000, Reach Out and Read: Texas.
Kathy L. Klos, SPH, UT M. D. Anderson Cancer Center, $10,778, A Mouse Model for Glomerulosclerosis and Early-Onset Renal Failure.
Bruce C. Kone, MS and GSBS, Astellas Pharma US Inc., $2,000, Texas Society of Academic Nephrologists (TXSAN) Meeting-Astellas Sponsored; Amgen Inc., $25,000, TXSAN Meeting-Amgen Sponsored.
Jary M. Lesser, MS, Wyeth Pharmaceuticals, $80,721, A Multi- Center, Randomized, Double-Blind, Long-Term Extension Study to Determine the Safety, Tolerability and Preliminary Long-Term Efficacy of Lecozotan (SRA-333) SR in Patients with Mild-to-Moderate Alzheimer's Disease.
Lenard M. Lichtenberger, MS and GSBS, Plx Pharma Inc., $25,000, Evaluation of PC-NSAID Formulations; Plx Pharma Inc.; $26,000, Evaluation of Therapeutic Effectiveness of PC [5-ASA] in a Rodent Model of Colitis.
F. Gerard Moeller, MS and GSBS, Baylor College of Medicine, $150,168, Cocaine Pharmacotherapy Targeting Dopamine & GABA.
Allison R. Ownby, MS, The University of Texas System, $5,000, Using Standardized Patients and Individual Learning Plans to Refine Residents' Professional Behavior and Communications Skills.
Andrew C. Papanicolaou, MS, University of Houston, $223,237, Cognitive, Instructional and Neuroimaging Factors in Math - Project 4.
Rade Paravina, DB and GSBS, Vita Zahnfabrik H. Rauter GMBH & Co. K.G., $8,400, Instrumental Evaluation of 3D Bleaching Shade Guide; Vita Zahnfabrik H. Rauter GMBH & Co. K.G., $8,400, Visual Evaluation of 3D Bleaching Shade Guide.
David J. Robinson, MS, UT System, $5,000, The Women's Early Comprehensive Cardiac Assessment and Risk Education Program (WECARE).
Emily K. Robinson, MS, Duke University Medical Center, $40,000, American College of Surgeons Oncology Group.
Michael W. Ross, SPH, UT Southwestern Medical Center, $14,497, STD/HIV Prevention Training Centers - Part II.
Jeremy Daniel Slater, MS, King Pharmaceuticals Research & Development, $55,700, A Phase Three, Randomized, Double-Blind, Parallel, Placebo-Controlled, Multi-Center Study, with Optional Open- Label Continuation, of the Efficacy and Safety of Vanquix Auto- Injector (Diazepam Injection) for the Management of Selected, Refractory Patients; Valeant Research & Development, $74,270, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel- Group, Phase Three Study to Determine the Efficacy and Safety of Retigabine (1200 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures.
Richard W. Smalling, MS, Novartis Pharmaceuticals Corp., $5,000, Grand Rounds Cardiology, Speaker Timothy Henry.
Keri C. Smith, MS, Lupus Foundation of America Inc., $65,000, Covalent Reactive Antigen Probes to Bind Auto-reactive Antibodies and Suppress B Cells in Lupus.
Rita D. Swinford, MS, St. Joseph's Hospital, $11,497, Focal Segmental Glomerulosclerosis Clinical Trial.
Oleg V. Tcheremissine, MS, Eli Lilly & Co., $74,135, Effects of Chronic Administration of Atomoxetine on Aggressive and Impulsive Responses.
Charles T. Van Buren, MS, Novartis Pharmaceuticals Corp., $130,468, A 24-Month, Multi-Center, Randomized, Open-Label, Non- Inferiority Study of Efficacy and Safety Comparing Concentration- Controlled in Two Doses (1.5 and 3.0 mg/Day Starting Doses) with Reduced Neoral vs. 1.44 mg Myfortic with Standard-Dose Neoral.
Sally W. Vernon, SPH, Veterans Administration Medical Center, $82,766, Assessing and Addressing Colorectal Cancer Screening Barriers; Veterans Administration Medical Center, $38,315, Home Telehealth Reminders to Improve Colonoscopic Preparation and Reduce No-Shows.
Nadarajah Vigneswaran, DB, UT M. D. Anderson Cancer Center, $50,000, Role of Emmprin/CD147 in the Progression of Oral Pre-malignancies. Hongbin Wang, School of Health Information Sciences (SHIS), State University of New York, $25,000, Toward Empirically Constraining CASIE.
Z. Hong Zhou, MS, University of Alabama at Birmingham, $32,943, Assembly of the Negative Stranded RNA Virus Core.
Jacqueline T. Hecht, MS and GSBS, Texas Department of State Health Services, $36,502, Texas Prevalence Study of Idiopathic Talipes Equinovarus (ITEV).
M. Sriram Iyengar, SHIS, National Space Biomedical Research Institute, $179,933, Medical Informatics and Healthcare Systems (MIHCS) Evidence-Based Medicine and Medical Informatics.
Previous story Next story